TABLE 2.
Signal detection for ciprofloxacin-, levofloxacin-, and moxifloxacin-associated tendonitis and tendon rupture.
| N | ROR (95%CI) | PRR (χ2) | IC (IC025) | EBGM (EBGM05) | |
|---|---|---|---|---|---|
| Tendonitis | |||||
| Ciprofloxacin | 905 | 98.50 (91.52–106.02) | 93.25 (67907.06) | 6.15 (6.04) | 76.80 (71.35) |
| Levofloxacin | 798 | 92.56 (85.68–100.00) | 87.80 (57748.29) | 6.08 (5.97) | 74.15 (68.63) |
| Moxifloxacin | 68 | 28.10 (22.07–35.78) | 27.58 (1719.91) | 4.28 (3.93) | 27.23 (21.38) |
| Tendon rupture | |||||
| Ciprofloxacin | 449 | 56.49 (51.14–62.40) | 55.01 (21118.00) | 5.46 (5.32) | 48.88 (44.25) |
| Levofloxacin | 536 | 76.38 (69.64–83.78) | 73.75 (33271.09) | 5.84 (5.70) | 63.89 (58.25) |
| Moxifloxacin | 33 | 17.23 (12.22–24.32) | 17.08 (495.81) | 3.49 (2.98) | 16.95 (12.01) |
N, number of adverse event reported; PRR, proportional reporting ratio; ROR, reporting odds ratio; IC, information component; EBGM, empirical Bayes geometric mean; CI, confidence interval; 95% CI, two‐sided for ROR; χ2, chi-squared; IC025 and EBGM05, lower one‐sided for IC and EBGM, respectively.